Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
Status:
RECRUITING
Trial end date:
2028-01-04
Target enrollment:
Participant gender:
Summary
Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual disease burden and improving recurrence-free survival. Enhanced visualization with BLC may lead to more accurate resections, potentially decreasing recurrence rates and improving long-term outcomes for bladder cancer patients. Patients will be randomized to either WLC TURBT or BLC TURBT, and outcomes will be measured using standard-of-care testing with cystoscopy and cytology, along with minimal residual disease (MRD) burden evaluation using urine next-generation sequencing.
Phase:
PHASE3
Details
Lead Sponsor:
Johns Hopkins University
Collaborator:
Photocure ASA
Treatments:
5-aminolevulinic acid hexyl ester Drug Delivery Systems